HK1128419A1 - Treatment of ischemic disease using erythropoietin - Google Patents

Treatment of ischemic disease using erythropoietin

Info

Publication number
HK1128419A1
HK1128419A1 HK09107647.3A HK09107647A HK1128419A1 HK 1128419 A1 HK1128419 A1 HK 1128419A1 HK 09107647 A HK09107647 A HK 09107647A HK 1128419 A1 HK1128419 A1 HK 1128419A1
Authority
HK
Hong Kong
Prior art keywords
erythropoietin
treatment
ischemic disease
ischemic
disease
Prior art date
Application number
HK09107647.3A
Other languages
English (en)
Inventor
Toshio Matsumoto
Tetsuya Kitagawa
Masahiro Abe
Masashi Akaike
Kazunari Nagayoshi
Kaname Yamamoto
Masato Higuchi
Original Assignee
Univ Tokushima
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokushima, Chugai Pharmaceutical Co Ltd filed Critical Univ Tokushima
Publication of HK1128419A1 publication Critical patent/HK1128419A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46433Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/14Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK09107647.3A 2006-06-07 2009-08-20 Treatment of ischemic disease using erythropoietin HK1128419A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006158998 2006-06-07
PCT/JP2007/061525 WO2007142288A1 (ja) 2006-06-07 2007-06-07 エリスロポエチンを用いた虚血性疾患の治療

Publications (1)

Publication Number Publication Date
HK1128419A1 true HK1128419A1 (en) 2009-10-30

Family

ID=38801534

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09107647.3A HK1128419A1 (en) 2006-06-07 2009-08-20 Treatment of ischemic disease using erythropoietin

Country Status (17)

Country Link
US (1) US20090280094A1 (zh)
EP (1) EP2047859A4 (zh)
JP (2) JP5326079B2 (zh)
KR (1) KR20090031547A (zh)
CN (1) CN101460188B (zh)
AR (1) AR061269A1 (zh)
AU (1) AU2007255717B2 (zh)
BR (1) BRPI0712063A2 (zh)
CA (1) CA2654154A1 (zh)
HK (1) HK1128419A1 (zh)
IL (1) IL195648A0 (zh)
MX (1) MX2008015392A (zh)
NO (1) NO20085098L (zh)
NZ (1) NZ573792A (zh)
RU (1) RU2008152746A (zh)
TW (1) TW200815026A (zh)
WO (1) WO2007142288A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007142288A1 (ja) * 2006-06-07 2007-12-13 The University Of Tokushima エリスロポエチンを用いた虚血性疾患の治療
EP3150701B1 (en) 2009-06-05 2018-10-03 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematopoietic cells
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations
CN101940594B (zh) * 2010-08-27 2013-12-04 上海士腾生物技术有限公司 用于治疗缺血性心血管疾病的制剂及其制备方法
CN101940590B (zh) * 2010-08-27 2013-09-18 上海士腾生物技术有限公司 促进创伤愈合的制剂及其制备方法
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
KR101544674B1 (ko) 2013-06-05 2015-09-02 서울대학교산학협력단 에리쓰로포이에틴으로 프라이밍된 혈관 생성능이 향상된 말초혈액 줄기세포 및 그 용도
DE102017116204B4 (de) 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501010A (ja) 1984-12-04 1987-04-23 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド エリトロポエチンの生産方法
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
CN1764470A (zh) * 2003-03-27 2006-04-26 詹森药业有限公司 ***在中风康复中的用途
BRPI0408829A (pt) * 2003-03-27 2006-04-04 Janssen Pharmaceutica Nv uso de eritropoietina em recuperação de acidente vascular cerebral
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
JP2007217283A (ja) * 2004-03-30 2007-08-30 Niigata Tlo:Kk 血管新生促進剤および血管新生療法
JP2006158998A (ja) 2004-12-02 2006-06-22 Nippon Sheet Glass Co Ltd ロッドの反り選別装置
KR20170027868A (ko) * 2005-08-05 2017-03-10 아라임 파마슈티칼즈, 인크. 조직 보호 펩티드 및 이의 용도
WO2007142288A1 (ja) * 2006-06-07 2007-12-13 The University Of Tokushima エリスロポエチンを用いた虚血性疾患の治療

Also Published As

Publication number Publication date
EP2047859A1 (en) 2009-04-15
KR20090031547A (ko) 2009-03-26
CA2654154A1 (en) 2007-12-13
AR061269A1 (es) 2008-08-13
CN101460188B (zh) 2013-09-04
CN101460188A (zh) 2009-06-17
RU2008152746A (ru) 2010-07-20
IL195648A0 (en) 2011-08-01
JP2013116919A (ja) 2013-06-13
NO20085098L (no) 2009-02-27
US20090280094A1 (en) 2009-11-12
AU2007255717A1 (en) 2007-12-13
BRPI0712063A2 (pt) 2011-12-20
TW200815026A (en) 2008-04-01
JP5326079B2 (ja) 2013-10-30
EP2047859A4 (en) 2010-05-05
JPWO2007142288A1 (ja) 2009-10-29
AU2007255717B2 (en) 2013-07-11
NZ573792A (en) 2011-09-30
WO2007142288A1 (ja) 2007-12-13
MX2008015392A (es) 2009-05-05

Similar Documents

Publication Publication Date Title
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
EP1982660A4 (en) TREATMENT ENDOSCOPE
DE602007011342D1 (de) Endoskop-Behandlungswerkzeug
GB0603041D0 (en) Therapeutic compounds
EP2160100B8 (en) Treatment of graft-versus-host disease
DK2402425T3 (da) Forbedret brygningsproces
DK2035369T3 (da) Terapeutiske
HK1128419A1 (en) Treatment of ischemic disease using erythropoietin
GB2476842B (en) Forceps
GB0700972D0 (en) Treatment of inflammatory disease
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
GB0619500D0 (en) Treatment of fibrosis
ZA201000225B (en) Treatment of depression
ZA200806505B (en) Treatment of HIV
GB0720976D0 (en) Treatment of inflammatory disease
GB0607952D0 (en) Novel treatment
EP2079704A4 (en) THERAPEUTIC COMPOUNDS
GB0723100D0 (en) Treatment of HFnEF
EP1959946A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
TWI367129B (en) Prufvorrichtung fur rohrbundelreaktoren
GB0623740D0 (en) Treatment of disease
GB0622136D0 (en) Treatment of gastrointestinal diseases
GB0622137D0 (en) Treatment of gastrointestinal diseases
GB0600446D0 (en) Improved Speculum

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170607